BETHESDA, Md., March 30, 2011 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today reported financial results for the year ended December 31, 2010.
Recent and Upcoming Highlights
Financial Results for the Year Ended December 31, 2010The net loss for 2010 was $7.7 million, or $0.43 per share, compared with a net loss of $9.1 million, or $0.62 per share, for 2009. Cash used to fund operations in 2010 was $8.7 million, compared with $7.8 million in 2009.
The Company's research and development (R&D) efforts are focused on the development of pharmaceuticals, particularly D-tagatose, a naturally occurring sugar and a low-calorie, full-bulk sweetener previously approved by the U.S. Food and Drug Administration (FDA) as a GRAS (Generally Recognized As Safe) food ingredient. Until June 2010, Biospherics' activities were limited to developing D-tagatose as a novel, first-in-class treatment for Type 2 diabetes. In June 2010, the Company announced that it will actively seek a pharmaceutical partner to continue the diabetes development and that it will also explore D-tagatose as a potential treatment for high triglycerides, a risk factor for atherosclerosis, myocardial infarction and stroke.
The clinical trials in the use of D-tagatose for the treatment of Type 2 diabetes have been the primary focus of the Biospherics segment, with R&D expenditures for 2010 and 2009 consisting of both a Phase 3 clinical trial and a related Phase 2 dose-range study. Included in 2009 R&D costs was an expense of $1.4 million for the purchase of D-tagatose. The Company's 2010 R&D expenses decreased by $1.98 million compared with 2009.
The Phase 3 trial to determine efficacy of D-tagatose as a treatment for Type 2 diabetes and the Phase 2 dose-range trial to evaluate the effectiveness of lower doses of D-tagatose in treating Type 2 diabetes were completed in late 2010. As Spherix has determined that it will take several additional years of clinical trials and could cost as much as several hundred million dollars to seek and obtain FDA approval for Dtagatose as a diabetes drug, the safety portion of the Phase 3 trial has been terminated.
In the fourth quarter of 2010, the Company began shifting the focus of its R&D efforts to the use of D-tagatose in lowering triglyceride levels, and anticipates a decrease in R&D costs in the initial years of the triglyceride studies compared with 2010 costs. Preclinical trials for the use of D-tagatose in lowering triglyceride levels will be conducted in 2011 and a human proof-of-concept trial may begin later in the year. The Company estimates that it will likely take three or more years to undertake the studies and clinical trials necessary to attract a pharmaceutical partner to complete development, and an additional 2-4 years to complete all necessary studies for an NDA filing.
Working capital was $4.9 million as of December 31, 2010, including $5.6 million in cash and cash equivalents.
"We believe this cash on hand, combined with the $2.6 million of net proceeds of the January 2011 offering, provide us with sufficient capital to fund operations for 2011 and into the following year as we work to complete a number of critical milestones," said Dr. Claire L. Kruger, CEO of Spherix. "Among these milestones are the results of several preclinical studies of the effects of D-tagatose in dyslipidemia and high triglycerides in high fat and high carbohydrate diets. In addition, we have begun a human clinical postprandial trial with Dtagatose in the treatment of high triglycerides. Data from this human trial are expected to be announced in the fall of 2011."
Business Update Conference Call and WebcastSpherix management will host a conference call to provide a business update and answer questions on Thursday, April 7, 2011, beginning at 11:00 a.m. Eastern time. To access the conference call, from the U.S. please dial (866) 322-1352 and from outside the U.S. please dial (706) 643-6246. All listeners should provide the following passcode: 56320911. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company's website, www.spherix.com.
Following the end of the conference call, a telephone replay will be available through April 14, 2011, and can be accessed by dialing (800) 642-1687 from the U.S. or (706) 645-9291 from outside of the U.S. All listeners should provide the following passcode: 56320911. The webcast will be available for 30 days.
Separately, Spherix announces that its Annual Shareholders Meeting, previously scheduled for May 17, 2011, will take place later this year and is tentatively scheduled for August 16, 2011.
About Spherix Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research. The Company now leverages its scientific and technical expertise and experience through its two subsidiaries – Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is dedicated to development of D-tagatose and recently completed a Phase 3 clinical trial to study the use of D-tagatose as a treatment for Type 2 diabetes. Biospherics is actively seeking a pharma partner to continue the diabetes development while exploring D-tagatose as a potential treatment for high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke. Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides. For more information, please visit www.spherix.com.
Forward-Looking Statements This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.- Tables Follow -Spherix IncorporatedConsolidated Statements of Operations20102009Revenue$
,359,110Operating expenseDirect costs
(517,677)(449,293)Research and development expense
(4,846,111)(6,830,957)Selling, general and administrative expense
(4,080,123)(3,265,137)Total operating expense
(9,443,911)(10,545,387)Loss from operations
6,10937,646Loss from continuing operations before taxes
(7,869,436)(9,148,631)Income tax benefit
133,194-Net loss(7,736,242)(9,148,631)Net (loss) income per share, basic
(0.62)Net (loss) income per share, diluted
(0.62)Weighted average shares outstanding, basic
18,061,32214,713,473Weighted average shares outstanding, diluted
18,061,32214,713,473Spherix IncorporatedConsolidated Balance SheetsASSETS20102009Current assetsCash and cash equivalents
9,026,002Short-term investments, held to maturity
-375,003Trade accounts receivable, net
74,110948Prepaid research expenses
464,322-Prepaid expenses and other assets
155,261209,255Total current assets
6,824,9909,885,361Property and equipment, net
154,161225,958Patents, net of accumulated amortization of $50,725 and $44,657
7,017,072$ 10,155,308LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilitiesAccounts payable and accrued expenses
,714,140Accrued salaries and benefits
170,64190,915Total current liabilities
2,576,8532,883,432Commitments and contingencies
--Stockholders' equityPreferred stock, $0.01 par value, 2,000,000 shares authorized;5,250 series B issued and 1 outstanding at December 31, 2010, none issued and outstanding at December 31, 2009
--Common stock, $0.005 par value, 50,000,000 shares authorized; 21,436,310 and 17,231,086 issued, 21,355,872 and 17,150,648outstanding at December 31, 2010 and 2009, respectively
107,18286,155Paid-in capital in excess of par value
38,483,06833,599,510Treasury stock, 80,438 shares, at cost at December 31, 2010 and 2009, respectively
(33,685,245)(25,949,003)Total stockholders' equity
4,440,2197,271,876Total liabilities and stockholders' equity
|SOURCE Spherix Incorporated|
Copyright©2010 PR Newswire.
All rights reserved